Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Summary

RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with relapsed or refractory multiple myeloma.

Timeline

Start

2005-03

Primary completion

2006-10

Completion

2008-08

Drugs

Indications